Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
Abstract: Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Type:
Grant
Filed:
January 4, 2002
Date of Patent:
November 4, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
Abstract: The invention provides methods to identify specific inhibitors of HPV E7 binding to CDK2 complex and methods to identify specific inhibitors of E7-induced CDK2 kinase activity. Specific inhibitors identified by the methods, compositions comprising the specific inhibitors, and methods of treatment using the compounds are also provided.
Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A&bgr; processing is altered.
Type:
Grant
Filed:
December 17, 1998
Date of Patent:
October 28, 2003
Assignee:
Pharmacia and Upjohn Company
Inventors:
Mark E. Gurney, Adele M. Pauley, Jinhe Li
Abstract: A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefor, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a pH of from 2.5-3.5 and a concentration of said doxorubicin of from 0.1 to 100 mg/ml.
Type:
Grant
Filed:
July 10, 2001
Date of Patent:
October 14, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Gaetano Gatti, Diego Oldani, Giuseppe Bottoni, Carlo Confalonier, Luciano Gambini, Roberto De Ponti
Abstract: The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.
Type:
Grant
Filed:
November 24, 2000
Date of Patent:
October 14, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
David E. Lowery, Timothy G. Geary, Teresa M. Kubiak, Martha J. Larsen
Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.
Abstract: The present invention provides methods of identifying agents that bind gene products critical for the survival of microbes, preferably Staphylococcus microbes, including agents that interfere with the expression of such gene products and agents that interfere with the function of such gene products.
Type:
Application
Filed:
May 2, 2003
Publication date:
September 25, 2003
Applicant:
PHARMACIA & UPJOHN COMPANY
Inventors:
Che-Shen C. Tomich, Cheryl L. Quinn, Staffan Arvidson, John E. Mott, Douglas W. Harris
Abstract: The present invention provides a compound of formula I
which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
Type:
Grant
Filed:
June 22, 2001
Date of Patent:
September 23, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
David John Anderson, Gordon L. Bundy, Fred L. Ciske, David R. Graber, Michael J. Genin, Thomas M. Judge, Malcolm Wilson Moon, Mark E. Schnute, Joseph Walter Strohbach, Suvit Thaisrivongs, Atli Thorarensen, Steven Ronald Turner, Valerie A. Vaillancourt, Allison J. Wolf
Abstract: The invention provides a compound of formula I:
wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
Abstract: Disclosed is a method of treating a non-topical infection selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of an Oxazolidinone.
Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA)
X2—CH2—C*H(OH)—CH2—NH—CO—RN (VIIIA)
and processes for production of pharmacologically useful oxazolidinones.
Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.
Abstract: This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Type:
Grant
Filed:
January 4, 2002
Date of Patent:
August 26, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.
Abstract: The present invention is a process for the conversion of bisnoralcohol to bisnoraldehyde (II), which is a known intermediate in the synthesis of progesterone.
Abstract: The invention provides methods and use of heterocyclic amines, and phenylazacycloalkane compounds, and their pharmacologically acceptable salts for the treatment of Restless Legs Syndrome (RLS).
Abstract: The invention provides compounds of Formula I:
These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
Type:
Grant
Filed:
August 17, 2001
Date of Patent:
July 29, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Jason K. Myers, Bruce N. Rogers, Vincent E. Groppi, Jr., David W. Piotrowski, Alice L. Bodnar, Eric Jon Jacobsen, Jeffrey W. Corbett